Cardiomyopathy and Cardiogenic Shock Caused by Juvenile Hemochromatosis Improving With Guideline-Directed Medical Therapy Despite High Ferritin Levels

Can J Cardiol. 2024 Apr;40(4):662-663. doi: 10.1016/j.cjca.2023.11.014. Epub 2023 Nov 18.

Authors

Alexandre Dessureault¹, Emmanuelle Massie¹, Douglas Fish², Marie-Claude Parent³

Affiliations

¹ Division of Cardiology, Montréal Heart Institute, Department of Medicine, Université de Montréal, Montréal, Québec, Canada.
² Division of Hematology, Montréal Heart Institute, Department of Medicine, Université de Montréal, Montréal, Québec, Canada.
³ Division of Cardiology, Montréal Heart Institute, Department of Medicine, Université de Montréal, Montréal, Québec, Canada. Electronic address: [email protected].

PMID: 37984779
DOI: 10.1016/j.cjca.2023.11.014

No abstract available

Publication types

Case Reports

MeSH terms

Cardiomyopathies* / complications
Ferritins
Hemochromatosis* / complications
Hemochromatosis* / congenital*
Hemochromatosis* / diagnosis
Humans
Shock, Cardiogenic / diagnosis
Shock, Cardiogenic / drug therapy
Shock, Cardiogenic / etiology

Substances

Ferritins

Supplementary concepts

Hemochromatosis, type 2